The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I Studies
Abstract
Purpose: PTK787/ZK 222584 (PTK/ZK), an orally active inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, inhibits VEGF-mediated angiogenesis. The pharmacodynamic effects of PTK/ZK were evaluated by assessing changes in contrast-enhancement parameters of metastatic liver lesions using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in patients with advanced colorectal cancer treated in two ongoing, dose-escalating phase I studies. Patients and Methods: Twenty-six patients had DCE-MRI performed at baseline, day 2, and at the end of each 28-day cycle. Doses of oral PTK/ZK ranged from 50 to 2000 mg once daily. Tumor permeability and vascularity were assessed by calculating the bidirectional transfer constant (Ki). The percentage of baseline Ki (% of baseline Ki) at each time point was compared with pharmacokinetic and clinical end points. Results: A significant negative correlation exists between the % of baseline Ki and increase in PTK/ZK oral dose and plasma levels (P = .01 for oral dose; P = .0001 for area under the plasma concentration curve at day 2). Patients with a best response of stable disease had a significantly greater reduction in Ki at both day 2 and at the end of cycle 1 compared with progressors (mean difference in % of baseline Ki, 47%, P = .004%; and 51%, P = .006; respectively). The difference in % of baseline Ki remained statistically significant after adjusting for baseline WHO performance status. Conclusion: These findings should help to define a biologically active dose of PTK/ZK. These results suggest that DCE-MRI may be a useful biomarker for defining the pharmacological response and dose of angiogenesis inhibitiors, such as PTK/ZK, for further clinical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
(2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,762
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Tofts, P. S., Brix, G., Buckley, D. L., Evelhoch, J. L., Henderson, E., Knopp, M. V., Larsson, H. B. W., Lee, T.-Y., Mayr, N. A., Parker, G. J. M., et al. (1999) · Journal of Magnetic Resonance Imaging · doi:10.1002/(sici)1522-2586(199909)10:3<223::aid-jmri2>3.0.co;2-s · Cited by 3,143
Clinical Applications of Research on Angiogenesis
Folkman, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512283332608 · Cited by 2,264
Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., & Keshet, E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5028 · Cited by 1,241
Dvorak, H. F., Nagy, J. A., Feng, D., Brown, L. F., & Dvorak, A. M. (1999) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-59953-8_6 · Cited by 743
Buadu, L. D., Murakami, J., Murayama, S., Hashiguchi, N., Sakai, S., Masuda, K., Toyoshima, S., Kuroki, S., & Ohno, S. (1996) · Radiology · doi:10.1148/radiology.200.3.8756909 · Cited by 465
Measuring Response in Solid Tumors: Unidimensional Versus Bidimensional Measurement
James, K., Eisenhauer, E., Christian, M., Terenziani, M., Vena, D., Muldal, A., & Therasse, P. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.6.523 · Cited by 401
Jain, R. K., Safabakhsh, N., Sckell, A., Chen, Y., Jiang, P., Benjamin, L., Yuan, F., & Keshet, E. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10820 · Cited by 374
Key factors in the acquisition of contrast kinetic data for oncology
Evelhoch, J. L. (1999) · Journal of Magnetic Resonance Imaging · doi:10.1002/(sici)1522-2586(199909)10:3<254::aid-jmri5>3.0.co;2-9 · Cited by 369
Vascular endothelial growth factor
Ferrara, N. (1996) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00387-5 · Cited by 355
Daldrup, H., Shames, D. M., Wendland, M., Okuhata, Y., Link, T. M., Rosenau, W., Lu, Y., & Brasch, R. C. (1998) · American Journal of Roentgenology · doi:10.2214/ajr.171.4.9762973 · Cited by 268
The effect of measuring error on the results of therapeutic trials in advanced cancer
Moertel, C. G., & Hanley, J. A. (1976) · Cancer · doi:10.1002/1097-0142(197607)38:1<388::aid-cncr2820380156>3.0.co;2-a · Cited by 257
Assessing tumor angiogenesis using macromolecular MR imaging contrast media
Brasch, R., Pham, C., Shames, D., Roberts, T., Van Dijke, K., Van Bruggen, N., Mann, J., Ostrowitzki, S., & Melnyk, O. (1997) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.1880070110 · Cited by 250
Erlemann, R., Sciuk, J., Bosse, A., Ritter, J., Kusnierz-Glaz, C. R., Peters, P. E., & Wuisman, P. (1990) · Radiology · doi:10.1148/radiology.175.3.2188300 · Cited by 231
MR imaging of tumor microcirculation: Promise for the new millenium
Taylor, J. S., Tofts, P. S., Port, R., Evelhoch, J. L., Knopp, M., Reddick, W. E., Runge, V. M., & Mayr, N. (1999) · Journal of Magnetic Resonance Imaging · doi:10.1002/(sici)1522-2586(199912)10:6<903::aid-jmri1>3.0.co;2-a · Cited by 223
Bold, G., Altmann, K.-H., Frei, J., Lang, M., Manley, P. W., Traxler, P., Wietfeld, B., Brüggen, J., Buchdunger, E., Cozens, R., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909443 · Cited by 217
Pham, C. D., Roberts, T. P. L., Van Bruggen, N., Melnyk, O., Mann, J., Ferrara, N., Cohen, R. L., & Brasch, R. C. (1998) · Cancer Investigation · doi:10.3109/07357909809039771 · Cited by 208
Inversion Recovery Snapshot FLASH MR Imaging
Haase, A., Matthaei, D., Bartkowski, R., Dühmke, E., & Leibfritz, D. (1989) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-198911000-00016 · Cited by 157
Su, M., Mühler, A., Lao, X., & Nalcioğlu, O. (1998) · Magnetic Resonance in Medicine · doi:10.1002/mrm.1910390213 · Cited by 133
Mayr, N. A., Hawighorst, H., Yuh, W. T. C., Essig, M., Magnotta, V. A., & Knopp, M. V. (1999) · Journal of Magnetic Resonance Imaging · doi:10.1002/(sici)1522-2586(199909)10:3<267::aid-jmri7>3.0.co;2-y · Cited by 97
The pivotal role of VEGF in tumor angiogenesis: Molecular facts and therapeutic opportunities
Siemeister, G., Martiny‐Baron, G., & Marmé, D. (1998) · Cancer and Metastasis Reviews · doi:10.1023/a:1006027124696 · Cited by 84
Self-citationMayr, N. A., Yuh, W. T. C., Zheng, J., Ehrhardt, J. C., Magnotta, V. A., Sorosky, J. I., Pelsang, R. E., Oberley, L. W., & Hussey, D. H. (1998) · American Journal of Roentgenology · doi:10.2214/ajr.170.1.9423627 · Cited by 76
Science, medicine, and the future: Antivascular therapy: a new approach to cancer treatment
Hayes, A. J., Li, L. Y., & Lippman, M. E. (1999) · BMJ · doi:10.1136/bmj.318.7187.853 · Cited by 56
Cited by
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Angiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Metadata
- Authors
- Morgan, B., Thomas, A. L., Drevs, J., Hennig, J., Buchert, M., Jivan, A., Horsfield, M. A., Mross, K., Ball, H. A., Lee, L., Mietlowski, W., Fuxius, S., Unger, C., O’Byrne, K., Henry, A., Cherryman, G. R., Laurent, D., Dugan, M., Marmé, D., & Steward, W. P.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-11-01
- Volume
- 21
- Issue
- 21
- Pages
- 3955-3964
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1507842220
- Cited by
- 652
- References
- 25
- FWCI
- 49.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.